Journal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume 4, Issue 5, Pages 551-560Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EGH.10.58
Keywords
cirrhosis; hepatocellular carcinoma; sorafenib; targeted therapy; translational; trial design
Categories
Funding
- NIH, National Cancer Institute, Center for Cancer Research
Ask authors/readers for more resources
The marked heterogeneity of hepatocellular carcinoma (HCC), particularly with regard to the etiology and severity of the underlying cirrhosis, makes clinical trial design in this disease very challenging. In addition, despite the global burden of HCC, there have been relatively few randomized studies. The major advance in medical therapy in HCC has been the benefit of sorafenib, as demonstrated in two Phase III studies. However, the benefit is small, and new therapies to augment or replace sorafenib are urgently needed. These newer therapies, as well as the progress made in two important areas - clinical trial design and molecular characterization - are the subject of this article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available